GlassScriptPhysician profile
William Taylor Payne
NPI 1376120246
$1,323.67
in general payments reported to CMS, 2019-2025
14 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $146 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $545.17 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $186.59 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $181.61 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $55.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.36 | 2025 | Jardiance |
| Amgen INC. | $48.56 | 2025 | Otezla, Repatha |
| Inspire Medical Systems, INC. | $48.10 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $39.79 | 2024-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $37.89 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $33.21 | 2024-2025 | Rexulti |
| Viiv Healthcare Company | $25.92 | 2025 | Apretude |
| Dynavax Technologies Corporation | $23.95 | 2025 | Heplisav-B |
| Abbott Laboratories | $22.30 | 2025 | Proclaim |
| Abbvie INC. | $21.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.